Abstract: Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells. It is a devastating disease with a poor prognosis and an average 5-year survival rate of about 30%. Disclosed herein are composition and methods for treating leukemia with a biomaterial comprising a polymer scaffold, a dendritic cell activating factor, a dendritic cell recruitment factor, and at least one leukemia antigen. The biomaterial-based vaccine disclosed herein promotes a potent, durable and transferable immune response against acute myeloid leukemia to prevent cell engraftment and synergizes with chemotherapy to prevent relapse.

Abstract: The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable as vaccines and/or for treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with a chemotherapeutic agent, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting piglets having maternally derived anti-Streptococcus suis antibodies against Streptococcus suis, by administering the vaccine to the piglets at an age of at most 28 days, preferably before the piglets are weaned.

Abstract: The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wall, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase; wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.

Abstract: This application discloses methods, compositions, and articles of manufacture for using NDV-induced serum to treat non-human mammals, including dogs, displaying severe neurological symptoms of advanced canine distemper virus (CDV) infection. An off-the-shelf chicken vaccine is injected into two or-more healthy mammals, of the same species as the sick animal, to provoke an immune response. After allowing several hours for the immune response to develop, blood is drawn from the healthy mammals and centrifuged to obtain serum. This “NDV-induced serum” can be injected into a mammal of the same species displaying severe neurological symptoms of advanced CDV infection on a prescribed schedule to bolster the sick animal's immune responses, preferably leading to clearance of the virus without the need for a spinal tap, which is the standard treatment for advanced CDV infection in mammals.

Abstract: The present invention relates to exogenous feline paramyxovirus genes, which are expressed from recombinant viral vector systems.

Abstract: The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 ?g per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.

Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based on the development of mutant CIV, having one or more mutations in segment 8, which induces a CIV-specific immune response in a subject.

Abstract: Provided herein are HIV-1 Env proteins or fragments thereof comprising one or more amino acid mutations; and nucleic acid molecule encoding the same. Further provided is a method of screening a compound for binding to one or more mutant HIV-1 Env proteins; and methods for eliciting an immune response against an HIV-1 infected cell, comprising administering to a subject an amount of a mutant HIV-1 Env protein, a fragment thereof a mutant HIV-1 Env trimeric complex, or portion thereof, effective to elicit an immune response in the subject. Further provided is a pharmaceutical composition, such as a vaccine, comprising the mutant HIV-1 Env protein or fragment thereof.

Abstract: The present disclosure is directed to antibodies that bind to DC-HIL on the surface of myeloid-derived suppressor cells, and thus antagonize the T cell suppressor function of these cells, as well as their use in diagnosing and treating cancers such as melanoma.

Abstract: The present invention is based, in part, on the novel discovery of the interaction between EWS-FLI1 and BAF complexes, and methods of modulating same to treat cancer, including Ewing Sarcoma.

Abstract: Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) in other embodiments. Hydrogel carrier materials for delivery of ISV agents and are also described herein.

Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.

Abstract: The present document describes a method for therapeutic indirect immunization of an optimally debulked human ovarian cancer patient having a CA125 antigen level in the blood above normal levels, comprising administering to said human patient a monoclonal antibody specific to CA125 antigen having at least a xenogeneic Fc region; an immune complex formed between CA125 antigen and said monoclonal antibody having at least a xenogeneic Fc region; or a combination thereof.

Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

Abstract: An immunothermosensitive composition is provided in the present disclosure. The immunothermosensitive composition includes a carrier and an immune adjuvant. The shell is carrier formed by self-assembly of a hydrophilic amine-containing polymer and a conductive polymer to form a hydrophilic region and a hydrophobic region, and the hydrophilic region is located outside the hydrophobic region. The immune adjuvant is coated in the hydrophobic region of the carrier, wherein the immune adjuvant specifically binds to Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8). The immunothermosensitive composition can absorb light energy to generate thermal energy and is maintained at a temperature greater than or equal to 39° C. and less than or equal to 45° C.

Abstract: The present invention relates to pegylated amino acid compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3A, R3B and n are as defined herein. The present invention also relates to compositions which comprise a pegylated amino acid compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a high concentration of an active biological ingredient (ABI). In embodiments of the invention, the ABI is an anti-PD-1 antibody or antigen binding fragment thereof that specifically binds human programmed death receptor 1 (PD-1). The invention further relates to methods for lowering the viscosity of an aqueous solution of a pharmaceutical composition comprising adding a compound of the invention to the solution.

Abstract: An improved local anesthetic solution with diminished bitter taste includes an anesthetic agent, an anesthetic solution vehicle, and a bitterness suppressant. The bitterness suppressant includes one or more compounds selected from the group consisting of: a sugar selected from the group consisting of monosaccharide sugars, disaccharide sugars, polysaccharide sugars, and combinations of the any of the foregoing; sweet-tasting compounds; acids; amino acids; salts; miscellaneous suppressant substances; and combinations of any of the foregoing. The improved local anesthetic solution optionally includes one or more additional agents selected from the group consisting of: buffering agents; vasoconstrictors; preservative compounds; stabilizers; contrast media agents; and combinations of any of the foregoing.

Abstract: Provided is an optimal intralymphatic preparation containing agents such as a drug, a cell, or a nucleic acid for use in a lymphatic drug delivery system. A drug-containing liquid preparation for delivering a chemical to a target lymph node by a lymphatic drug delivery system, wherein the liquid has an osmotic pressure of 700 to 2,700 kPa.

Abstract: Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.

Abstract: The present invention relates to a new drug delivery composition comprising a polymer-drug matrix wherein both a drug and a polymer-degrading enzyme are included. The invention further relates to a process for preparing such a drug delivery composition.

Abstract: The present invention relates to compositions providing improved preservative efficacy. The present invention further relates to polyquaternium compound containing compositions having improved the antifungal activity. In certain embodiments, the present invention relates to ophthalmic compositions comprising a polyquaternium compound, a polyol or combination of polyols, borate compound, and an antimicrobial mixture comprising electrolytes and nutrients.

Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.

Abstract: Theranostic agents useful for imaging and treating metastatic cancer are provided. The theranostic agents comprise a TMTP1 peptide conjugated to an albumin binding moiety to prolong circulation lifetime and a chelating agent to allow complexation of a diagnostic metal ion with the theranostic agent. The theranostic agent can be conjugated, for example, to a positron-emitting metal radionuclide suitable for PET imaging such as 64Cu, 68Ga, 44Sc, 86Y, 89Zr, or 82Rb; or a gamma-emitting metal radionuclide suitable for single photon emission computed tomography (SPECT) imaging such as 67Ga, 99mTc, 111In, or 177Lu. Alternatively, theranostic agents can be conjugated with a paramagnetic metal ion suitable for use in magnetic resonance imaging (MRI) such as manganese (e.g., Mn2+), iron (e.g., Fe3+, Fe2+) or gadolinium (e.g., Gd3+). Such theranostic agents show selective uptake by metastatic cancer cells and are useful for PET, SPECT, or MRI imaging of metastatic cells in vitro and in vivo.

Abstract: The present invention provides a bioconjugation method and compounds for use therein. The bioconjugation method comprises the step of conjugating a biological molecule containing a first unsaturated functional group with a payload comprising a second unsaturated functional group, wherein the first and second unsaturated functional groups are complementary to each other such that conjugation is a reaction of said functional groups via a Diels-Alder reaction which forms a cyclohexene ring.

Abstract: The present invention provides a method for producing an exosome that transfers an active substance specifically to a target and the exosome produced by the same; a method for delivering the active substance to the target tissue using the exosome; a pharmaceutical composition for delivery of the active substance comprising the exosome as an active ingredient; and a composition for preparing the exosome comprising an expression vector wherein the target peptide is inserted into an extracellular portion of a transmembrane protein.

Abstract: Provided herein are methods for treating a disease or disorder associated with mitochondrial dysfunction through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a subject in need of treatment. The nucleic acid molecule may include a functional human frataxin (hFXN) or may include a gene editing system that when transfected into the cells removes a trinucleotide extension mutation of endogenous hFXN.

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: The present invention includes methods for transferring a multigenic phenotype to a cell by transfecting, preferably by phototransfection, and locally transfecting a cell or a cellular process with a laser while the cell is bathed in a fluid medium comprising two or more nucleic acids, thereby introducing the nucleic acid into the interior of the cell. Expression of the nucleic acids results in a multigenic phenotype in the transfected cell.

Abstract: Echolucent implantable materials may delivered to a selected placement site and biodegrade after a certain period of time. Applications include delivery of therapeutic agents to the placement site.

Abstract: Echolucent implantable compositions are described. Applications include materials for delivering of therapeutic agents to a tissue at a placement site.

Abstract: Echolucent implantable compositions are described. Applications include materials for delivering of therapeutic agents to a tissue at a placement site.

Abstract: Nanoparticles, compositions, and methods are disclosed for manufacturing and using the nanoparticles and compositions for cellular tracking, drug encapsulation, and biologic tracking.

Abstract: Presented herein are methods and compositions for non-invasive imaging of TAMs with discoidal high-density lipoproteins to assess prognosis and therapy outcome. TAMs are increasingly investigated in cancer immunology, and are considered a promising target for better and tailored treatment of malignant growths. Although TAMs also have high diagnostic and prognostic value, TAM imaging still remains largely unexplored. Imaging agents/methods provided herein are of value for non-invasive in vivo evaluation of TAM burden, not only in preclinical but also in clinical settings.

Abstract: A novel method for rapidly and efficiently introducing fluorine into the P-C-P backbone of bisphosphonates starting from readily accessible diazomethylenebisphosphonate esters is provided. The method is applied successfully to create novel [18F]-labeled bisphosphonates for positron emission tomography imaging. Some versions of the method include reacting a diazomethylenebisphosphonate tetraalkyl ester with a fluorinating agent in the presence of an acidic HF/base complex and a t-butyl hypohalite to produce a halofluoromethylenebisphosphonate tetraalkyl ester, and dealkylating the halofluoromethylenebisphosphonate alkyl ester to produce a halofluoromethylenebis(phosphonic acid). Methods of replacing the halogen group with hydrogen are further provided. 18F-labeled bisphosphonates prepared by the methods, and methods of using such compounds for positron emission tomography imaging in patients and animal models, are also provided.

Abstract: Methods for in vivo immunoimaging including: (a) administering a labeled-antibody conjugate to a subject, wherein the labeled-antibody conjugate includes: an antibody that specifically recognizes and binds to IFN-?, and a detection label conjugated to the antibody, wherein the detection label is a radionuclide tracer or fluorophore; and (b) detecting the presence of the radiolabeled-antibody conjugate in the subject in vivo by imaging. Embodiments of the present disclosure are directed to labeled-antibody conjugates and therapeutic radionuclide-antibody conjugates.

Abstract: The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer.

Abstract: Devices, methods, and systems for disinfection with light are disclosed. In some examples, a lighting source is operable to provide light at wavelength range of about 380 nm-420 nm with an irradiance and/or dosage sufficient for disinfection. One or more sensors and a control system may be used to control operation of the lighting source, such as by adjusting the lighting source in response to various inputs.

Abstract: The present invention relates to a high-intensity ultraviolet light emitting diodes (6) (UV-LED) device (1) for preventing biofouling formation in a system for subsea operation of a target fluid. Further, the present invention discloses such device for coupling or integration into a subsea treatment system and to a process using such device.

Abstract: A portable UV-C disinfection apparatus, method, and system for ultraviolet germicidal irradiation. UV-C emitters may be coupled to an array housing having a planar array surface in a vertical configuration. UV-C sensors are configured to measure the amount of UV-C light or near UV-C light from a target surface. A controller may be communicably engaged with the UV-C sensors to determine the amount of UV-C radiation collected by the UV-C sensors. The controller includes instructions stored on a memory according to the amount of UV-C radiation collected corresponding to an effective kill-dose for surface disinfection. The improved apparatus, method, and system reduces exposure time by varying the intensity and wavelength of the UV-C administered, while concurrently reducing UV overexposure to surfaces by administering radiation through a rotational zonal application.

Abstract: An article, a system, and a method for indication of treatment are provided. The article comprises a first body, a second body, and a treatment indicator. The first body comprises a first axis, a cavity, a first port, and a second port. The cavity is positioned within the first body and configured to receive the second body. The second body comprises a second axis, a chamber, a third port, and a fourth port. The article is configured to move between a first configuration and a second configuration. In the first configuration, the first port is aligned with the third port to form a fluid pathway to the chamber, and the second port is aligned with the fourth port to form a fluid pathway to the chamber. In the second configuration, the first port is misaligned with the third port, and the second port is misaligned with the fourth port.

Abstract: An apparatus and method for reducing dosage time in ultraviolet germicidal irradiation systems. A UV-C reflective adhesive film may be configured as sheets, or in a roll that may be cut to a desired size or shape. A user may apply the UV-C reflective adhesive film to a desired surface of an interior room by exposing an adhesive surface to the desired interior surface. A reflective layer of the UV-C reflective adhesive film is configured to improve the reflectance percentage or reflectance pattern of a desired interior surface with respect to incident UV-C or near UV-C light. The improved reflectance properties of the desired surface functions to reflect a greater amount of light back to one or more closed-loop sensors in operation with a UV-C or near UV-C germicidal irradiation system.

Abstract: A lamp includes a lamp body, an acoustics mounted in the lamp body, a light source device mounted in the lamp body, and a humidifying device mounted in the lamp body. The lamp body includes a base, a mounting seat mounted on the base, and a lampshade mounted on the mounting seat. The base has an interior provided with a water storage chamber. The acoustics is mounted in the base. The light source device is mounted on the mounting seat. The humidifying device is mounted on the mounting seat. The humidifying device includes a humidifier mounted on the mounting seat, and a water drawing stick extending through the mounting seat. The water drawing stick has a lower end extending into the water storage chamber, and an upper end connected to the humidifier.

Abstract: An enclosed space air treating assembly includes a compartment having an interior. The compartment has an air inlet and an air outlet, wherein pressurized air enters into the interior through the air inlet and exits the interior through the air outlet. Pressurized air received by the air inlet is defined as received air. An atomizer is in fluid communication with the interior and supplies atomized fluid to the received air within the interior such that that the atomized fluid is carried outwardly through the air outlet. A control is in communication with the atomizer. The control turns on the atomizer intermittently for a preselected amount of time while the pressurized air flows through the compartment.

Abstract: A method, system, and apparatus for sterilization, decontamination, and antimicrobial therapeutic treatment, which may include a dispensing device to cover a person, plant, animal, surface, enclosure, room or other structure or area with an antimicrobial solution. Radiation sources may expose the antimicrobial agent to a certain wavelength of radiation. The combination of the solution and the radiation may create a synergistic reaction that causes an effect greater than the radiation or solution separately. The same reaction creates a residual antimicrobial effect. A container, area or passageway including an dispensing device a solution so that a person, plant, animal or object is covered or saturated with an antimicrobial solution.

Abstract: A photocatalytic reactor for use in a heating, ventilation and/or air conditioning system, and comprises a longitudinal housing having a wall and allowing air or gas to pass through along the longitudinal direction of the longitudinal housing. A plurality of tubes are positioned in the longitudinal housing and arranged such that some outer tubes are positioned closer to the housing wall than some inner tubes. The tubes have their longitudinal axis parallel with the longitudinal axis of the longitudinal housing allowing the air or gas to pass along and through the tubes and the tubes comprise photocatalytic material in or on their tube walls. The system comprises an irradiation system for irradiating the photocatalytic material for inducing catalytic action. The irradiation system and plurality of tubes are configured so that upon irradiating by the irradiation system photocatalytic material of the outer tubes and inner tubes is irradiated.

Abstract: A wound dressing material includes a particle having a crosslinked gelatin derivative, the gelatin derivative having the structure represented by the following formula (1): GltnNH—CHR1R2??(1) wherein “Gltn” represents a gelatin residue, R1 represents an alkyl group having 1-17 carbon atoms, and R2 represents a hydrogen atom or an alkyl group having 1-17 carbon atoms, and the particle having a particle size ranging from 1 to 1,000 ?m.